Suppr超能文献

使用补充和替代医学针对严重流感期间的宿主反应。

Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

机构信息

Research School of Biology, The Australian National University, Canberra and Chinese Treatment Centre, Suite 4 Professional Centre, Turner, Australia.

出版信息

Evid Based Complement Alternat Med. 2010 Dec;7(4):501-10. doi: 10.1093/ecam/nep152. Epub 2009 Sep 24.

Abstract

It is now accepted that an overwhelming inflammatory response is the cause of human deaths from avian H5N1 influenza infection. With this in mind we sought to examine the literature for examples of complementary and alternative medicines that reduce inflammation, and to place the results of this search in the context of our own work in a mouse model of influenza disease, using a pharmaceutical agent with anti-inflammatory properties. Two Chinese herbs, Angelica sinensis (Dang Gui) and Salvia miltiorrhiza (Danshen), have been recently shown to protect mice during lethal experimental sepsis via inhibition of the novel inflammatory cytokine High Mobility Group Box 1 protein (HMGB1). Biochanin A, a ligand of the peroxisome proliferator activated receptors (PPAR) alpha and gamma and the active isoflavone in Trifolium pratense (red clover), has anti-inflammatory properties, and thus could be used as an influenza treatment. This is of great interest since we have recently shown that gemfibrozil, a drug used to treat hyperlipidemia in humans and a synthetic ligand of PPAR alpha, significantly reduces the mortality associated with influenza infections in mice. The inflammation-modulating abilities of these natural agents should be considered in light of what is now known about the mechanisms of fatal influenza, and tested as potential candidates for influenza treatments in their own right, or as adjunct treatments to antivirals.

摘要

现在人们已经接受,强烈的炎症反应是导致人类感染禽流感 H5N1 后死亡的原因。考虑到这一点,我们试图在文献中寻找可以减轻炎症的补充和替代药物的例子,并将这一搜索结果放在我们自己在流感疾病小鼠模型中使用具有抗炎特性的药物的工作背景下。两种中药,当归(当归)和丹参(丹参),最近被证明通过抑制新型炎症细胞因子高迁移率族蛋白 1(HMGB1)来保护实验性败血症小鼠。生物黄酮 A 是过氧化物酶体增殖物激活受体(PPAR)α和γ的配体,也是三叶草(红三叶草)中的活性异黄酮,具有抗炎作用,因此可用于治疗流感。这非常令人感兴趣,因为我们最近发现,吉非贝齐,一种用于治疗人类高脂血症的药物,也是 PPARα的合成配体,可显著降低小鼠流感感染相关死亡率。鉴于目前对致命性流感的机制的了解,应考虑这些天然药物的抗炎调节能力,并将其作为流感治疗的潜在候选药物进行测试,或者作为抗病毒药物的辅助治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1369/2892358/843cb23dd834/nep152f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验